Dr. Garon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2020 Santa Monica Blvd., 6th Floor
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-5471- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of ChicagoResidency, Internal Medicine, 1999 - 2002
Washington University in St. Louis School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2003 - 2026
IL State Medical License 1999 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2004 Oct 28
- Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Jan 01
- Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 01
- Join now to see all
Publications & Presentations
PubMed
- A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by...Edward B Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Dmytro Trukhin, Sang-We Kim, Grygorii Ursol, Maen Hussein, Farah Loui...> ;Clinical Lung Cancer. 2024 Mar 15
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.Brahmer, J., Long, G., Hamid, O., Garon, E., Herbst, R., Andre, T., Armand, P., Bajorin, D., Bellmunt, J., Burtness, B., Choueiri, T., Cohen, E., Diaz, L., Shitara, K....> ;European Journal of Cancer. 2024 Mar 1
- Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.Margarita Majem, Ethan Basch, David Cella, Edward B Garon, Roy S Herbst, Natasha B Leighl> ;Lung Cancer. 2024 Jan 1
- Join now to see all
Journal Articles
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung CancerEdward B Garon, Maeve Waldron-Lynch, The New England Journal of Medicine
Lectures
- Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Controversies, Difficult Questions Arise in NSCLC Amid New DataFebruary 2024
Press Mentions
How a Biomarker Test Saved This Lung Cancer Survivor’s LifeNovember 30th, 2022- ESMO: DESTINY-Lung01 Demonstrates Trastuzumab Deruxtecan Benefit in NSCLCSeptember 20th, 2021
- Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic AlterationsSeptember 19th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
UCLA Medical Center-Santa MonicaSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
